Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EPS (Basic) (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed EPS (Basic) for 15 consecutive years, with $3.98 as the latest value for Q2 2025.

  • Quarterly EPS (Basic) rose 585.58% to $3.98 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $3.99 through Dec 2025, up 417.48% year-over-year, with the annual reading at -$2.26 for FY2025, 20.98% up from the prior year.
  • EPS (Basic) for Q2 2025 was $3.98 at Aytu Biopharma, up from $0.01 in the prior quarter.
  • The five-year high for EPS (Basic) was $3.98 in Q2 2025, with the low at -$35.9 in Q1 2022.
  • Average EPS (Basic) over 5 years is -$4.51, with a median of -$0.77 recorded in 2021.
  • The sharpest move saw EPS (Basic) crashed 6117.14% in 2021, then surged 585.58% in 2025.
  • Over 5 years, EPS (Basic) stood at -$8.74 in 2021, then surged by 75.4% to -$2.15 in 2022, then skyrocketed by 98.14% to -$0.04 in 2023, then surged by 150.41% to $0.02 in 2024, then skyrocketed by 19647.61% to $3.98 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at $3.98, $0.01, and $0.02 for Q2 2025, Q1 2025, and Q4 2024 respectively.